Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.46 |
| ▸ | CTSD | P07339 | 6/20 | 0.39 |
| ▸ | REN | P00797 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429165 | 0.81 | BACE1 (0.43) | BACE1CTSDBACE2 | |
| SCHEMBL7720227 | 0.80 | BACE1 (0.43) | BACE1CTSDBACE2 | |
| SCHEMBL448218 | 0.78 | BACE1 (0.44) | BACE1CTSDBACE2 | |
| SCHEMBL429062 | 0.71 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL427954 | 0.70 | BACE1 (0.53) | BACE1CTSD | |
| SCHEMBL430737 | 0.70 | BACE1 (0.61) | BACE1CTSDBACE2 | |
| SCHEMBL431009 | 0.69 | BACE1 (0.60) | BACE1CTSD | |
| SCHEMBL428986 | 0.69 | BACE1 (0.70) | BACE1CTSDBACE2 | |
| SCHEMBL12247462 | 0.68 | BACE1 (0.58) | BACE1CTSD | |
| SCHEMBL15606184 | 0.66 | BACE1 (0.41) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885REN 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.